Take a trial of UK to unlock this pageFind out more

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2009 2010 2011 2012 2013 2014 TTM 2015E 2016E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 13th Aug, paid: 14th Sep more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ +1.8%

FINANCIAL BRIEF: For the six months ended 30 June 2015, AstraZeneca plc revenues decreased 6% to $12.36B. Net income decreased 4% to $1.25B. Revenues reflect United States segment decrease of 56% to $2.17B, Western Europe segment decrease of 59% to $1.34B. Net income also reflects Finance expense increase of 15% to $537M (expense), Distribution Costs increase of 8% to $161M (expense). Dividend per share remained flat at $0.90. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
C+
C+
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 30th Jun '15) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2015
31st Dec 2016

Price Target: $75.1
(+10.91% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +0.2% ($) (¢) (¢) ($) (¢) (¢)
Consensus Estimate
1m Change
3m Change
32 brokers Broker Consensus Trend
Broker Recommendations for AstraZeneca
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 2 3 16 8 5

Named Brokers and Analysts
Jefferies Jeffrey Holford , Credit Suisse Matthew Weston , SEB Equities Lars Hevreng , Leerink Partners LLC Seamus Fernandez , BERNSTEIN Tim Anderson , Danske Markets Martin Parkhøi Mattias Häggblom Thomas Bowers , Seymour Pierce , Panmure Gordon Savvas Neophytou , Natixis Philippe Lanone Jean-Jacques Le Fur , Mirabaud Securities Nicholas Turner , Swedbank Markets Johan Unnerus , Nordea Markets Erik Hultgaard , Davy , CA Cheuvreux , Societe Generale Justin Smith , Handelsbanken Capital Markets Peter Sehested , Pareto Securities AS Yilmaz Mahshid , Berenberg Alistair Campbell , DZ Bank , Oddo Securities Sebastien Malafosse , Helvea SA Odile Rundquist , Kepler Cheuvreux Sheela Sharma , Charles Stanley Rae Ellingham , Shore Capital Stockbrokers Brian White , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Liberum Naresh Chouhan , Baader Helvea Equity Research Odile Rundquist ,

Profile Summary

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company's medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. The Company's pipeline includes 133 projects, of which 118 are in the clinical phase of development. AstraZeneca operates in over 100 countries.

Directors: Pascal Soriot (CEO) 56, Marc Dunoyer (CFO) 62, Fiona Cicconi (EVP) , Ruud Dobber (EVP) , Paul Hudson (EVP) , Bahija Jallal (EVP) , Mark Mallon (EVP) , Luke Miels (EVP) , Briggs Morrison (EVP) , Menelas Pangalos (EVP) , Leif Johansson (NEC) , Cornelia Bargmann (NED) , Genevieve Berger (NED) 60, Ann Cairns (NED) 58, Marcus Wallenberg (NED) 59,

No. of Employees: 57,500 No. of Shareholders: 100,371


Last Annual December 31st, 2014
Last Interim June 30th, 2015
Incorporated June 17, 1992
Public Since September 21, 2007
Shares in Issue 1,263,665,297
Free Float 1.26bn (99.8%)

Address - Legal Department 2 Kingdom Street, LONDON, W2 6BD, United Kingdom
Web http://www.astrazeneca.com/
Phone +44 20 73045000
Contact Thomas Larsen (IR Contact Officer)
Auditors KPMG LLP

AZN Share Price Performance AZNQuote
4382.5p
40.5  0.9%
Traded 4:26pm · Minimum 15 min delayed · NMS: 0.500k

Latest AZN News Announcements (delayed)

Upcoming AZN Events
Wednesday 12th August, 2015
Dividend For AZN.BA
Wednesday 12th August, 2015
Dividend For AZN
Thursday 13th August, 2015
Dividend For AZN.L
Thursday 5th November, 2015
Q3 2015 AstraZeneca PLC Earnings Release

Recent ↓
Thursday 30th July, 2015
Q2 2015 AstraZeneca PLC Earnings Call
Thursday 30th July, 2015
AstraZeneca PLC Split For AZN.BA
Thursday 30th July, 2015
Q2 2015 AstraZeneca PLC Earnings Release
Friday 24th July, 2015
AstraZeneca PLC Split For AZN
Monday 15th June, 2015
AstraZeneca PLC at Citi European Healthcare Conference
Tuesday 2nd June, 2015
AstraZeneca PLC Analysts and Investors Briefing during the American Society of Clinical Oncology (ASCO) Annual Meeting
Friday 24th April, 2015
AstraZeneca PLC Annual Shareholders Meeting
Friday 24th April, 2015
Q1 2015 AstraZeneca PLC Earnings Call
Friday 24th April, 2015
Q1 2015 AstraZeneca PLC Earnings Release
Wednesday 25th March, 2015
AstraZeneca PLC at Biotechnology Industry Organization (BIO) Asia International Conference
Monday 16th March, 2015
AstraZeneca PLC Investor Science Conference Call ACC 2015
Thursday 19th February, 2015
Dividend For AZN.L
Wednesday 18th February, 2015
Dividend For AZN
Wednesday 18th February, 2015
Dividend For AZN.BA
Thursday 5th February, 2015
Full Year 2014 AstraZeneca PLC Earnings Call
Thursday 5th February, 2015
Full Year 2014 AstraZeneca PLC Earnings Release
Wednesday 14th January, 2015
AstraZeneca PLC at JPMorgan Healthcare Conference
Tuesday 18th November, 2014
AstraZeneca PLC Investor Day
Thursday 6th November, 2014
Q3 2014 AstraZeneca PLC Earnings Call
Thursday 6th November, 2014
Q3 2014 AstraZeneca PLC Earnings Release


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2015.


Should you buy AZN

Access AZN Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder